New hope for hepatitis c relapse: triple therapy shows promise
NCT ID NCT00780910
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if this combination could make the virus undetectable 24 weeks after treatment ended. Participants could not have cirrhosis, liver failure, or certain mental health conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Conditions
Explore the condition pages connected to this study.